Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NextGen restructures management as it gears up for assay launches

This article was originally published in Clinica

Executive Summary

Biomarker specialist NextGen Sciences (Ann Arbor, Michigan) has appointed Neal Siegel to the new role of director of assay development. Dr Siegel, who previously worked at Sword Diagnostics and Abbott Labs, will oversee assay delivery, validation and quality control at NextGen. The company has also appointed Glenn Barney vice-president of business development. Formerly of Decision Biomarkers, Mr Barney will help drive sales growth across all NextGen products. He will also lead the firm’s marketing activities, and will be joined by the new director of marketing, Hiroshi Saito, who joins from internet and digital marketing agency Optiem. The new appointments come as NextGen prepares to launch two new biomarker assays markets in the first half of this year; one is a human plasma assay targeting several oncology disease areas, and the other is a human cerebrospinal fluid assay for central nervous system disorders.

You may also be interested in...

Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?

Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.

Roche Dx' EMEA Head To Take Charge After Diggelmann Departs

Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.

Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio

Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts